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Abstract 54 
Objective: To test for interactions between apolipoprotein (APOE) e4 genotype, and 55 
lifestyle factors on worse cognitive abilities in UK Biobank.  56 
Methods: Using UK Biobank cohort data, we tested for interactions between APOE e4 57 
allele presence, lifestyle factors of alcohol intake, smoking, total physical activity and 58 
obesity, and sex, on cognitive tests of reasoning, information processing speed and 59 
executive function (n range=70,988-324,725 depending on the test). We statistically 60 
adjusted for potential confounders of age, sex, deprivation, cardiometabolic conditions, 61 
and educational attainment.   62 
Results: There were significant associations between APOE e4 and worse cognitive 63 
abilities, independent of potential confounders, and between lifestyle risk factors and 64 
worse cognitive abilities, however there were no interactions at multiple correction-65 
adjusted P<0.05, against our hypotheses.  66 
Conclusions: Our results do not provide support for the idea that e4 genotype increases 67 
vulnerability to the negative effects of lifestyle risk factors on cognitive ability, but rather 68 
support a primarily outright association between APOE e4 genotype and worse cognitive 69 
ability.     70 
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Introduction 71 
There is some evidence that associations between known lifestyle-based risk factors for 72 
worse cognitive abilities - e.g. diabetes1, stress2, traumatic brain injury3, lower exercise4, 73 
or air pollution5, and female sex6,7 – are larger in terms of effect size in people who 74 
possess an APOE e4 allele (vs. possessing non-risk e2 or e3 alleles). With regards 75 
dementia as an outcome, there are similar findings for physical activity, dietary fat, 76 
alcohol intake and smoking8. Essentially: people with the e4 allele may be more 77 
vulnerable to the effects of lifestyle risk factors on cognitive faculties. The potential 78 
biological rationale for this is that the APOE locus moderates lipid metabolism which 79 
influences brain-relevant factors like white matter myelination and neuronal repair; 80 
meaning e4 carriers may be more ‘frail’ and vulnerable to the negative effects of sub-81 
optimal lifestyle risk factors9,10. There have been instances of null results, however11. It is 82 
also possible that there is a degree of ‘file-drawer’ where null results are less likely to be 83 
published12. There have been few large-scale systematic investigations into whether 84 
APOE e4 interacts with lifestyle risk factors associated with worse cognitive abilities, in a 85 
single cohort with a standard methodological procedure. 86 
 87 
 UK Biobank is a large general population cohort with approximately 502,000 88 
participants13. All participants have baseline medical, cognitive and sociodemographic 89 
data, and genetic data. We hypothesised that there would be a significant statistical 90 
interaction where known lifestyle factors would have larger associations with cognitive 91 
abilities in people who possessed APOE e4 genotype (vs. non-e4).     92 
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Methodology 93 
Study design and participants 94 
The UK Biobank cohort is a large prospective general population cohort where baseline 95 
assessment took place between 2006 and 2010 in 22 assessment centres13. In total, 96 
502,628 participants aged 40–70 years were recruited from the general population. 97 
Invitation letters were sent to eligible adults registered with the NHS and living within 98 
25 miles of a study assessment centre. Participants completed a comprehensive touch-99 
screen questionnaire including sociodemographic characteristics, physical and mental 100 
health, and a brief battery of cognitive tests. Across 2014-2015, participants that had 101 
provided an email address were invited to complete a remote, web-based questionnaire 102 
including cognitive tests. The project was completed using application number 17689 (PI: 103 
Lyall).  104 
 105 
Cognitive assessment  106 
At baseline assessment participants completed five tests of cognitive ability, which were 107 
novel and computerised. We have described these in detail, in an open-access report14. 108 
For the current study, we focussed on the two tests that showed acceptable intra-109 
participant stability across on average 4 years (intraclass r range = 0.54 to 0.65). In the 110 
first test, most participants completed a timed test of symbol matching, like the common 111 
card game ‘Snap’ hereafter referred to as reaction time (RT). The second test was a task 112 
with 13 logic/reasoning-type questions and a 2-min time limit, labelled as ‘fluid 113 
intelligence’ and referred to here simply as reasoning15. The maximum score is 13. The 114 
reasoning task was only added to the battery part way through the baseline assessment 115 
phase and so around n=~150k participants completed it.  116 
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We did not examine the baseline tests of pairs-matching, prospective memory or 117 
numeric memory. The pairs-matching task was markedly zero-inflated (indicating floor 118 
effect) and did not show good longitudinal stability in n=~20k with repeat data (r<0.2 119 
across four years on average); prospective memory had around 94% overall success rate  120 
and thus had a degree of ceiling effect, and numeric memory was only completed by 121 
around n=48k overall and did not have longitudinal data to suggest good reliability. These 122 
considerations have been described previously14.  123 
 124 
After baseline assessment (2006-2010), between 2014 and 2015 participants were 125 
invited to complete a web-based questionnaire, where responders  completed, amongst 126 
other things, web-based versions two well-known cognitive tasks called ‘Trail making 127 
test A/B’ (TMT-A and TMT-B; processing speed and speed/executive function 128 
respectively) and ‘Digit symbol substitution’ (executive function), each sensitive to the 129 
effects of cognitive ageing16,17. Independent studies have shown good correlation 130 
between computerized vs. paper-and-pen versions of the tests18,19. 131 
 132 
Sociodemographic and medical data 133 
Participants were asked during the baseline assessment about any previous or current 134 
cardiometabolic conditions that had been diagnosed by their doctor. Specifically, 135 
participants were asked whether their doctor had diagnosed myocardial infarction, 136 
angina, stroke, hypertension or diabetes. We defined coronary heart disease (CHD) as 137 
either myocardial infarction or angina. We excluded participants who stated only ‘prefer 138 
not to answer’.  139 
 140 
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Participants reported their highest educational attainment and this was recoded into a 141 
simpler college/university degree vs. no degree variable. Townsend deprivation indices 142 
were derived from postcode of residence20. This provides an area-based measure of 143 
socioeconomic deprivation derived from aggregated data on car ownership, household 144 
overcrowding, owner occupation and unemployment. Higher Townsend scores equate to 145 
higher levels of area-based socioeconomic deprivation.  146 
 147 
Physical activity was self-reported and weighted for intensity: self-reported minutes of 148 
walking (×3.3), moderate exercise (×4.0) and vigorous exercise (×8.0; this is a common 149 
calculation21). These were then summated to create an overall physical activity score, 150 
which was then split into quintiles to simplify analysis.  151 
 152 
Participants whose BMI was 40 or over were considered very severely obese as per 153 
World Health Organisation (WHO) guidelines; we chose a cut-off of 40 rather than say 30 154 
(‘moderately obese’) because there is evidence of reverse causality where moderately 155 
high BMI can show a protective effect under some circumstances22.  (Note that final 156 
results were virtually identical when we used a BMI of 30 as a cut-off).  157 
 158 
In terms of smoking we compared ‘never’ vs. ‘current’ smokers.  Frequency of alcohol 159 
intake was recorded as never, special occasions only, 1–3 times per month, 1–2 times per 160 
week, 3–4 times per week, daily/almost daily. Because our interest is in high vs. low 161 
alcohol intake we split this into a binary variable: participants who reported ‘Daily or 162 
almost daily’ (i.e. high) vs. ‘One to three times a month’; ‘Special occasions only’ and 163 
‘Never’ (i.e. low). Participants were asked if there was a reason they had stopped 164 
drinking, e.g. due to doctor’s advice, health precaution etc.: participants who reported 165 
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this were removed from analysis, to help reduce confounding where low alcohol intake 166 
was due to poor health.   167 
 168 
Genetic data 169 
UK Biobank genotyping was conducted by Affymetrix using a bespoke BiLEVE Axiom 170 
array for ∼50,000 participants and the remaining ∼450,000 on the Affymetrix UK 171 
Biobank Axiom array. All genetic data were quality controlled by UK Biobank as described 172 
by the protocol paper23. The APOE e genotype is directly genotyped. Further information 173 
on the genotyping process is available (http://www.ukbiobank.ac.uk/scientists-174 
3/genetic-data), including detailed technical documentation 175 
(https://biobank.ctsu.ox.ac.uk/crystal/docs/genotyping_sample_workflow.pdf). The 176 
two APOE e SNPs – rs7412 and rs429358 – were both in Hardy Weinberg equilibrium 177 
(P>0.05) assessed with PLINK V1.9024. 178 
 179 
Standard Protocol Approvals, Registrations, and Patient Consents 180 
This secondary-data analysis study was conducted under generic approval from the NHS 181 
National Research Ethics Service (approval letter dated 17th June 2011, ref 182 
11/NW/0382). Written informed consent was obtained from all participants in the study 183 
(consent for research, by UK Biobank).  184 
 185 
Data availability statement 186 
UK Biobank is an open access resource available to verified researchers upon application 187 
(http://www.ukbiobank.ac.uk/). Analysis syntax is available upon request.   188 
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Statistical analysis  189 
We used two models: partially adjusted and fully adjusted. The partially adjusted model 190 
was statistically corrected for the potential confounders of: age, sex, genotypic array, 191 
assessment centre and eight genetic principal components (PCs; to correct for potential 192 
stratification). The fully adjusted model was additionally corrected for Townsend 193 
deprivation scores, self-reported diabetes, CHD, hypertension, and university/college 194 
degree (‘yes’ vs. ‘no’)1. We report descriptive statistics according to EQUATOR guidelines. 195 
The dependent variables in the linear regression were the cognitive scores for reasoning, 196 
log RT, log TMT A and B, and Digit symbol scores. 197 
 198 
We first tested for associations between APOE e4 and lifestyle factors on cognitive 199 
abilities, using linear regression and reporting standardized betas (i.e. on a per-SD scale 200 
of effect). We then tested for two-way interactions between APOE e4 genotype with male 201 
vs. female sex, and e4 with lifestyle factors. Finally, we tested for additional three-way 202 
interactions (APOE; sex; lifestyle). TMT and reaction time scores were log-transformed 203 
due to a positive skew. We removed outliers above 3.30 SDs from the mean (<0.1%). We 204 
corrected for multiple testing using the False Discovery Rate (FDR)25,26. Power 205 
calculations were performed using G*Power 327. Stata V.14 was used for statistical 206 
analyses. For additional comparison with previous meta-analyses, we have provided 207 
Cohen’s d effect size estimates for unadjusted APOE e4/cognitive associations. All 208 
supplementary tables and figures are available from Dryad.  209 
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Results 210 
Descriptives   211 
There were 487,377 participants with APOE e genotype data. We excluded participants 212 
with non-white British ancestry, self-report vs. genetic sex mismatch, putative sex 213 
chromosomal aneuploidy, excess heterozygosity, and missingness rate >0.1. This left 214 
n=408,228. We removed participants who reported a neurological condition (~5%; see 215 
Lyall et al.14); the inclusion of which could drive type-1 errors due to skewed results 216 
(results were unchanged when we included these participants). This left 389,778 217 
participants. Finally, we accounted for relatedness between participants by removing one 218 
random participant in cases where two individuals were 1st cousins or closer. This left 219 
326,535 participants for whom genotype frequencies of APOE were e2/e2 n=2,133 (1%), 220 
e2/e3 n=40,460 (12%), e2/e4=8,348 (3%), e3/e3=189,728 (58.0%), e3/e4 n=77,963 221 
(24%) and e4/e4 n=7,923 (2%). Descriptive statistics for cognitive scores and 222 
cardiometabolic conditions are shown in Tables 1 and 2, and demographic factors are 223 
show in Supplementary table e-1.  224 
 225 
The mean age at baseline was 56.79 (standard deviation [SD] = 8.00), and 150,071 (46%) 226 
participants were male. The mean age at time of completing the internet tests was 61.8 227 
years (SD=7.60). Using an APOE e4 present vs. absent model excluding e2/e4 228 
(protective/risk alleles) genotype carriers, results in sample sizes per group of: e4+ 229 
n=85,886 (e3/e4; e4e4) vs. e4- n=232,301 (e2/e2; e2/e3; e3/e3), total n=318,187. In 230 
terms of cognitive data: reasoning data were available in n=105,913, reaction time in 231 
n=324,725, TMT A (processing speed) in n=70,988 and B (speed plus executive function) 232 
in n=71,055, with Digit symbol substitution (executive function) in n=79,840. All 233 
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significant phenotypic/genetic associations with cognitive abilities reported hereafter 234 
remained significant after correction for type-1 error.  235 
 236 
A power calculation showed that based on a Cohen’s D of 0.1 (a ‘small’ effect size being 237 
0.2) and group difference ratio of 2:1 (based arbitrarily on never vs. current smoker 238 
ratio), 95% power to detect an effect would be achieved at n=4,872, suggesting the 239 
current analyses have generally good power.  240 
 241 
[Table 1 here] 242 
 243 
APOE e4 and lifestyle associations with cognitive abilities 244 
Table 3 shows standardised beta associations between APOE e4 genotype, lifestyle 245 
factors, and cognitive abilities: there were significant associations between e4 genotype 246 
and worse log TMT-A times (fully adjusted model standardised beta = 0.032, 95% CI = 247 
0.016 to 0.048, P<0.001), TMT-B times (fully adjusted standardised beta = 0.047, 95% CI 248 
= 0.032 to 0.062, P <0.001) and Digit symbol substitution scores (fully adjusted 249 
standardised beta = -0.054, 95% CI = -0.068 to -0.040, P<0.001). 250 
Unadjusted APOE e4/cognitive score associations were of very small magnitude 251 
(i.e. under 0.2) for each of log RT (Cohen’s d = 0.003), reasoning (d = -0.003), log TMT A 252 
(d = -0.014), log TMT B (-0.023), and Digit symbol coding (d = 0.035). Effect sizes were 253 
similar for untransformed RT and TMT A/B values. 254 
 255 
In terms of lifestyle factors: there were significant associations for smoking with 256 
reasoning, TMT-A and -B times and Digit symbol substitution scores (all P<0.001; Table 257 
1). There were significant associations for alcohol intake and obesity, but the sign of these 258 
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associations changed for alcohol and obesity where they appeared protective in the fully 259 
adjusted models for various tests. Physical activity did not significantly associate with any 260 
cognitive outcomes.  When all analyses were corrected for type-1 error with FDR, all 261 
significant associations remained statistically significant (FDR-adjusted P-values 262 
all<0.05).  263 
 264 
[Table 2 here] 265 
 266 
Two-way interactions: APOE e4 and sex; APOE e4 and lifestyle.  267 
We tested for APOE e4 by sex interactions, with the results shown in Supplementary 268 
Table e-2. There were two significant interactions: for log RT (fully-adjusted model 269 
P=0.045), and fluid reasoning (P=0.034). Stratifying by sex using the fully-adjusted 270 
models showed that the e4 effect was stronger in males vs. females for log RT (P = 0.068 271 
vs. 0.375 respectively) although still non-significant; and not appreciably different for 272 
fluid reasoning scores (P = 0.155 vs. 0.136). For Digit symbol substitution there was a 273 
significant interaction between e4 and obesity (final model P value <0.001). Stratified, 274 
this appeared to be due to a significantly deleterious effect of e4 genotype in non-obese 275 
participants (fully-adjusted standardized beta = -0.058, 95% CI = -0.072 to -0.044, P 276 
<0.001), but protective in obese participants (fully-adjusted standardized beta = 0.176, 277 
95% CI = 0.058 to 0.295, P = 0.004). All other tested two-way interactions were not 278 
significant (P>0.05).  279 
 280 
[Table 3 here]  281 
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Three-way interactions: APOE e4, sex, and lifestyle.  282 
We tested for significant APOE e4/sex/lifestyle interactions, with the results shown in 283 
Supplementary Table e-3. All interactions were non-significant except one. The 284 
significant interaction was for e4 presence, sex and high alcohol intake (i.e. daily or 285 
almost daily) vs. not on reasoning scores (P=0.020). Supplementary Figure e-1 shows that 286 
the interaction was principally driven by males having a larger association between high 287 
alcohol intake and better reasoning (compared with females). While visually an e4 effect 288 
becomes slightly larger in the context of high alcohol intake, pairwise comparisons did 289 
not show this to be statistically significant (P>0.05). When all analyses were corrected for 290 
type-1 error with FDR, all significant interactions attenuated to non-significance (FDR-291 
adjusted P-values all >0.05). The total model adjusted r2 values ranged from 0.02 to 0.22 292 
(i.e. 2% to 22% of total variance explained). 293 
 294 
Additional analyses 295 
As post-hoc analyses we additionally repeated all tests for collated (potentially 296 
protective) APOE e2/e2 plus e2/e3 genotypes, vs. neutral e3/e3. We also repeated the 297 
analyses with log-transformed (+1) pairs-matching error scores as an outcome. There 298 
were no significant associations or interactions once adjusted for FDR (all q-values 299 
P>0.100; results are available upon request).  300 
It is possible that e4 genotype and lifestyle are not independent. Logistic 301 
regressions showed that participants who possessed the e4 allele were significantly less 302 
likely to smoke (OR = 0.95, 95% CIs = 0.93 to 0.98, P<0.001) and more likely to have a 303 
degree (OR = 1.02, 95% CIs = 1.00 to 1.03, P = 0.043) although the effect sizes were small, 304 
and carriers showed no differences in other lifestyle factors (see Supplementary Table e-305 
4, which shows all intercorrelations).  306 
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The protective effect of alcohol intake on cognitive ability is counter-intuitive, 307 
having removed people who reported stopping due to ill health. Descriptive statistics of 308 
alcohol intake by APOE e4 genotype status are shown in Supplementary Table e-5.  309 
 310 
Discussion 311 
This study hypothesized that based on previous studies in smaller cohorts, together with 312 
biological rationale, risk factors for worse cognitive ability such as smoking history, 313 
(high) alcohol intake, obesity, and lower physical activity, would interact with APOE e4 314 
genotype, such that each risk factor’s association with worse cognitive scores would be 315 
larger in e4 carriers (vs. non-carriers). We also investigated the moderating role of sex28. 316 
We found that associations between APOE e4 and cognitive scores were of relatively 317 
small effect size, and only suggestive interactions with sex where e4 males scored worse 318 
than females (which did not survive correction for multiple testing; and in any case the 319 
within-sex e4 effects were not nominally significant). We also found some small, 320 
counterintuitive suggestive results e.g. that severe obesity and daily drinking could be 321 
protective. These findings could reflect: test imprecision, the generally preserved and 322 
healthy sample (i.e. selection or attrition biases), underestimation of e4’s true effect (due 323 
to attrition), or that previous studies perhaps overstated the true effect. Our findings 324 
generally support a ‘direct’ route of APOE e4 genotype to cognitive decline rather than 325 
increasing vulnerability to other factors.  326 
 327 
In this study we report negative associations between smoking and worse cognitive 328 
ability, which fits the established literature29; although surprisingly protective 329 
associations from high alcohol intake (i.e. daily) and obesity defined here as BMI of 40 330 
and above (aka severely obese), even after adjusting for prevalent diseases and 331 
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accounting as much as possible for people whose alcohol intake had significantly changed 332 
in recent years due to ill health (i.e. factors which might cause reverse causality). This is 333 
more likely to reflect selection or collider bias in some way 30: e.g. where the participants 334 
who drink more/are highly obese and respond positively to the invitation for assessment, 335 
are quite selected31, rather than the association being causal.  This is also the most likely 336 
explanation for e4 carriers having better scores (vs. non-carriers) in the context of severe 337 
obesity in this study. In any case the interactions were null after correction for type-1 338 
error with FDR. There was no association from weighted physical activity, although the 339 
sample size for that variable was much smaller than others. There were significant 340 
associations between APOE e4 genotype and worse TMT-A, TMT-B, and Digit symbol 341 
substitution scores which fits previous literature that e4 genotype is deleterious for 342 
processing speed and executive function32.  343 
 344 
There were mostly no statistically significant interactions between lifestyle factors and 345 
APOE e4 genotype. The e4/cognitive associations were of quite small magnitude, 346 
compared to previous meta-analyses33. Power analysis estimates showed that we had 347 
relatively good power to detect an association; although it is still possible that the lack of 348 
association reflects a lack of power. Alternative interpretations include that that the UK 349 
Biobank participants have perhaps not deteriorated markedly with age or are in 350 
generally good health, and/or are slightly too young (mean age 56 at baseline) to show 351 
significant effects of APOE e4 genotype, which can show a larger association with 352 
cognitive function with increasing age34 or longitudinally32. Further to this there may be 353 
sex effects which vary by age window: for example Neu et al.35 found that APOE e3/e4 354 
genotype was associated with earlier age at onset of Alzheimer’s disease (AD)  (vs. men; 355 
total N = 57,979), and Hohman et al.36 reported significant interaction between e4 356 
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presence (vs. absence) and female (vs. male) sex on higher total cerebrospinal total and 357 
phosphorylated tau (a neuropathological marker of AD).  Additional interactions which 358 
we did not assess are also possible, e.g. between APOE e4, sex and deprivation level, and 359 
this will be an interesting area of future research.  360 
 It is possible that the lack of interaction reflects a degree of selection bias where 361 
the sample includes ‘healthier’ carriers of the e4 genotype (generally reported as 362 
deleterious), and its effect in this cohort is therefore underestimated to an extent.  363 
Our results slightly contrast with our previous findings in around n=110k UK 364 
Biobank participants, where we reported a significant deleterious interaction between 365 
e4 genotype and reasoning scores (P<0.001), however this (and all other tests) did not 366 
survive correction for additional covariates e.g. depression, Townsend scores, and 367 
cardiometabolic conditions in that study.  368 
 369 
We have reported previously on potential limitations of the novel baseline tests: namely 370 
that the reasoning test includes some 'crystallized' (i.e. accumulated knowledge) items 371 
which are not strictly reasoning, and the reliabilities are poorer across time compared 372 
with more standard, validated cognitive tests14. We did not report on UK Biobank 373 
memory scores because our previous analysis has shown that a) the test was not reliable 374 
across time14 and b) e4 had no major association with scores in n=110k anyway1. The 375 
web-based tests are more akin to existing validated cognitive batteries, but their use over 376 
the internet in this instance has not been characterised and there may be some 377 
inaccuracies due to internet connection lag etc., or computer problems in people’s homes. 378 
It is possible that the interaction between e4 genotype and lifestyle risk factors has been 379 
overstated due to publication bias, particularly given many studies are quite small in 380 
terms of sample size37. On the other hand, the large sample size used here may increase 381 
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risk of statistically significant findings which are of such small magnitude as to not be 382 
practically or clinically significant.  383 
The UK Biobank does not have a metric of premorbid, lifetime cognitive ability in its 384 
participants. This could be an important limitation where ‘brighter’ young adults are less 385 
likely to engage in unhealthy behaviours, or in midlife, people with better cognitive ability 386 
may be better able to manage their healthcare, take medications reliably etc. 38.  387 
 388 
Genetic modification of phenotypic risk factors on cognitive ability has enormous 389 
potential implication for prevention of cognitive impairment in an ageing population. 390 
Future research may seek to investigate this question in brain imaging phenotypes 391 
(available in UK Biobank although in smaller numbers), as these factors are less 392 
'downstream' of the effects of genetic variation compared with cognitive scores, which 393 
can be affected by state-dependent factors like stress or anxiety39.  394 
 395 
This study aimed to test for interactions between APOE e4, lifestyle and sex on cognitive 396 
abilities. We found suggestive interaction test results where men were more vulnerable 397 
to e4 genotype (in terms of cognition). Caveats to this were that the effect sizes were 398 
small, and there may be biases at play (e.g. where e4’s effects are underestimated in the 399 
data). Our results therefore provide less support for the idea that e4 genotype increases 400 
vulnerability to the negative effects of lifestyle risk factors, but rather support a primarily 401 
outright association between APOE e4 genotype and worse cognitive ability.   402 
 403 
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Table 1: demographic descriptive statistics.  
 
  
  APOE e4 absent 
(n=232,301; 73%) 
APOE e4 present 
(n=85,886; 27%)  
Age in years Mean (SD) 56.82 (8.00) 56.71 (8.00) 
Sex Male N (%) 106,694 (46%) 49,491 (46%) 
Townsend 
deprivation score 
Mean (SD) -1.59 (2.92) -1.60 (2.92) 
    
Alcohol intake, N 
(%) 
≤3 times per 
month 
56,819 (53.08) 20,792 (52.94) 
 Daily 50,219 (46.92) 18,484 (47.06) 
 Missing 2,054 1,848 
Current smoker, N 
(%) 
Current 23,366 (15.52) 8,237 (14.88) 
 Never 127,185 (84.48) 47,134 (85.12) 
 Missing   
Total physical 
activity quintile 
1st  1,634 (20%) 610 (21%) 
 2nd 1,590 (20%) 560 (20%) 
 3rd 1,651 (20%) 547 (19%) 
 4th 1,648 (20%) 587 (20%) 
 5th 1,596 (20%) 559 (20%) 
 Missing  224,209 83,023 
    
Severely obese 
(BMI≥40), N (%) 
 No 227,454 (97.91) 84,127 (97.95) 
 Yes 4,847 (2.09) 1,759 (2.05) 
 Missing 8,185 163 
Degree, N (%) Yes 73,820 (32%) 27,616 (32%) 
 No 156,602 (68%) 57,567 (68%) 
 Missing 1,879 703 
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Table 2: cognitive score descriptive statistics.   
 
  
 APOE e4 absent  APOE e4 
present  
Reasoning scores, mean (SD) 
 
6.20 (2.10) 6.21 (2.10) 
Log transformed reaction time score, mean 
(SD) 
6.30 (0.18) 6.30 (0.18) 
Untransformed median (IQR)  
 
535 (477-606) 535 (477-605) 
Digit symbol substitution scores, mean (SD) 19.87 (5.14) 19.69 (5.26) 
   
Log transformed Trail making test-A times, 
mean (SD) 
3.60 (0.30) 3.60 (0.31) 
Untransformed median (IQR)  35.33 (29.03 to 
44.29) 
35.51 (29.10 to 
44.59) 
Log transformed Trail making test-B times, 
mean (SD) 
4.12 (0.32) 4.12 (0.32) 
Untransformed median (IQR)  60.32 (49.07 to 
75.48) 
60.80 (49.33 to 
76.17) 
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Table 3: individual associations between APOE e4, lifestyle and cognitive phenotypes. 
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 Partially adjusted 95% CI’s  Fully adjusted 95% CI’s  
 Standardised b lower upper p Standardised b lower upper p 
Log reaction time         
APOE e4 0.002 -0.006 0.009 0.678 0.002 -0.005 0.010 0.555 
Smoking 0.118 0.106 0.129 <0.001 0.070 0.058 0.082 <0.001 
Alcohol -0.108 -0.118 -0.098 <0.001 -0.075 -0.085 -0.065 <0.001 
Obesity 0.082 0.060 0.105 <0.001 0.022 -0.001 0.045 0.064 
Physical activity -0.004 -0.016 0.008 0.557 -0.005 -0.017 0.007 0.438 
Fluid reasoning scores         
APOE e4 0.003 -0.011 0.017 0.673 <0.001 -0.013 0.013 0.964 
Smoking -0.236 -0.257 -0.214 <0.001 -0.084 -0.104 -0.063 <0.001 
Alcohol 0.289 0.271 0.307 <0.001 0.169 0.152 0.187 <0.001 
Obesity -0.137 -0.178 -0.095 <0.001 -0.019 -0.058 0.021 0.355 
Physical activity 0.004 -0.019 0.027 0.741 0.011 -0.011 0.033 0.311 
Log TMT-A times         
APOE e4 0.031 0.015 0.047 <0.001 0.032 0.016 0.048 <0.001 
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Smoking 0.084 0.056 0.113 <0.001 0.043 0.014 0.072 0.003 
Alcohol -0.081 -0.102 -0.059 <0.001 -0.051 -0.072 -0.029 <0.001 
Obesity 0.020 -0.036 0.076 0.487 -0.033 -0.089 0.023 0.249 
Physical activity -0.009 -0.032 0.014 0.453 -0.012 -0.035 0.012 0.323 
Log TMT-B times         
APOE e4 0.044 0.028 0.059 <0.001 0.047 0.032 0.062 <0.001 
Smoking 0.197 0.170 0.225 <0.001 0.133 0.106 0.161 <0.001 
Alcohol -0.093 -0.114 -0.072 <0.001 -0.039 -0.060 -0.018 <0.001 
Obesity 0.081 0.027 0.136 0.003 -0.005 -0.059 0.049 0.857 
Physical activity -0.005 -0.028 0.018 0.672 -0.007 -0.030 0.015 0.524 
Digit symbol scores         
APOE e4 -0.054 -0.068 -0.040 <0.001 -0.054 -0.068 -0.040 <0.001 
Smoking -0.151 -0.177 -0.126 <0.001 -0.091 -0.117 -0.066 <0.001 
Alcohol 0.115 0.095 0.134 <0.001 0.069 0.049 0.088 <0.001 
Obesity -0.117 -0.167 -0.067 <0.001 -0.044 -0.094 0.006 0.085 
Physical activity 0.011 -0.010 0.032 0.302 0.013 -0.008 0.033 0.222 
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Partially adjusted: age, sex, assessment centre, genotypic array. Fully adjusted: (also) Townsend deprivation scores, degree yes vs. no, self-report 
diabetes, hypertension and CHD.
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Supplementary Table e-1: cardiometabolic condition frequencies.  
 
 
  APOE e4 
absent  
APOE e4 
present  
Diabetes  Yes 11,081 (5%) 3,756 (4%) 
 No 220,729 
(95%) 
81,962 
(96%) 
 Missing 491 168 
Hypertension  Yes 61,426 
(26%) 
22,814 
(27%) 
 No 170,529 
(74%) 
62,939 
(73%) 
 Missing 346 133 
Coronary heart disease  Yes 9,492 (4%) 4,001 (5%) 
 No 81,752 
(96%) 
81,752 
(95%) 
 Missing 346 133 
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Supplementary Table e-2: individual two-way interactions between APOE e4 genotype and variables, on cognitive phenotypes. 
 Partially adjusted Fully adjusted 
 Standardised b lower upper p Standardised b lower upper p 
Log reaction time         
APOE e4*sex 0.02 <0.01 0.03 0.043 0.02 <0.01 0.03 0.045 
APOE e4*smoking <0.01 -0.03 0.02 0.717 <0.01 -0.03 0.02 0.832 
APOE e4*alcohol 0.01 -0.01 0.03 0.415 0.01 -0.01 0.03 0.522 
APOE e4*obesity -0.04 -0.09 0.01 0.140 -0.03 -0.09 0.02 0.204 
APOE e4*physical activity <0.01 -0.03 0.03 0.911 <0.01 -0.03 0.03 0.943 
Fluid reasoning scores         
APOE e4*sex 0.02 <0.01 0.05 0.082 0.03 <0.01 0.05 0.034 
APOE e4*smoking -0.03 -0.08 0.02 0.255 -0.03 -0.08 0.02 0.187 
APOE e4*alcohol 0.02 -0.02 0.06 0.224 0.03 -0.01 0.06 0.162 
APOE e4*obesity 0.04 -0.06 0.13 0.459 0.04 -0.05 0.13 0.437 
APOE e4*physical activity 0.04 -0.01 0.09 0.148 0.02 -0.03 0.07 0.425 
Log TMT-A times         
APOE e4*sex <0.01 -0.03 0.03 0.985 <0.01 -0.03 0.03 0.977 
APOE e4*smoking -0.01 -0.07 0.06 0.877 <0.01 -0.06 0.07 0.989 
APOE e4*alcohol -0.03 -0.08 0.01 0.166 -0.03 -0.08 0.01 0.151 
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APOE e4*obesity <0.01 -0.13 0.12 0.945 <0.01 -0.13 0.13 0.952 
APOE e4*physical activity 0.03 -0.03 0.08 0.312 0.02 -0.03 0.08 0.368 
Log TMT-B times         
APOE e4*sex 0.01 -0.02 0.04 0.581 0.01 -0.02 0.04 0.540 
APOE e4*smoking -0.01 -0.08 0.05 0.701 <0.01 -0.06 0.06 0.998 
APOE e4*alcohol 
-0.04 -0.08 0.01 0.109 -0.04 -0.09 0.00 0.075 
APOE e4*obesity -0.01 -0.14 0.11 0.829 -0.01 -0.14 0.11 0.860 
APOE e4*physical activity 0.03 -0.03 0.08 0.343 0.02 -0.03 0.07 0.452 
Digit symbol scores         
APOE e4*sex -0.01 -0.04 0.02 0.556 -0.01 -0.04 0.02 0.544 
APOE e4*smoking 0.05 -0.01 0.11 0.076 0.04 -0.01 0.10 0.135 
APOE e4*alcohol -0.02 -0.06 0.02 0.324 -0.02 -0.06 0.02 0.370 
APOE e4*obesity 0.23 0.11 0.35 <0.001 0.22 0.11 0.34 <0.001 
APOE e4*physical activity 0.02 -0.03 0.06 0.505 0.02 -0.03 0.07 0.390 
Partially adjusted: age, sex, assessment centre, genotypic array. Fully adjusted: (also) Townsend deprivation scores, degree yes vs. no, 
self-report diabetes, hypertension and CHD. Each dependent variable (cognitive score) is underlined in the left-hand column. 
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Supplementary Table e-3: individual three-way interactions between APOE e4 genotype, sex, and lifestyle variables, on cognitive 
phenotypes. 
 Partially adjusted Fully adjusted 
 Standardised b lower upper p Standardised b lower upper p 
Log reaction time         
APOE e4*sex*smoking -0.02 -0.06 0.03 0.495 -0.02 -0.06 0.03 0.489 
APOE e4*sex*alcohol 0.03 <0.01 0.07 0.039 0.03 <0.01 0.07 0.043 
APOE e4*sex*obesity -0.01 -0.12 0.10 0.845 -0.02 -0.13 0.09 0.726 
APOE e4*sex*physical activity <0.01 -0.02 0.03 0.715 <0.01 -0.02 0.03 0.810 
Fluid reasoning scores         
APOE e4*sex*smoking 0.04 -0.05 0.13 0.430 0.04 -0.04 0.13 0.342 
APOE e4*sex*alcohol 0.06 <0.01 0.12 0.035 0.07 0.01 0.12 0.017 
APOE e4*sex*obesity 0.06 -0.13 0.26 0.521 0.08 -0.11 0.27 0.407 
APOE e4*sex*physical activity <0.01 -0.05 0.04 0.861 0.01 -0.04 0.05 0.799 
Log TMT-A times         
APOE e4*sex*smoking 0.01 -0.12 0.13 0.931 0.01 -0.12 0.13 0.923 
APOE e4*sex*alcohol 0.01 -0.05 0.08 0.650 0.02 -0.05 0.08 0.591 
APOE e4*sex*obesity -0.04 -0.31 0.24 0.790 -0.04 -0.31 0.23 0.761 
APOE e4*sex*physical activity 0.02 -0.03 0.07 0.425 0.02 -0.03 0.06 0.459 
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Log TMT-B times         
APOE e4*sex*smoking 0.09 -0.03 0.21 0.152 0.08 -0.03 0.20 0.164 
APOE e4*sex*alcohol -0.01 -0.07 0.06 0.842 -0.01 -0.07 0.06 0.870 
APOE e4*sex*obesity -0.02 -0.29 0.25 0.871 -0.01 -0.27 0.26 0.960 
APOE e4*sex*physical activity 0.03 -0.02 0.07 0.231 0.02 -0.02 0.07 0.295 
Digit symbol scores         
APOE e4*sex*smoking -0.01 -0.12 0.10 0.815 -0.03 -0.13 0.08 0.652 
APOE e4*sex*alcohol 0.02 -0.04 0.07 0.597 0.01 -0.04 0.07 0.608 
APOE e4*sex*obesity -0.09 -0.34 0.15 0.462 -0.11 -0.36 0.13 0.366 
APOE e4*sex*physical activity <0.01 -0.04 0.05 0.860 <0.01 -0.04 0.05 0.860 
Partially adjusted: age, sex, assessment centre, genotypic array. Fully adjusted: (also) Townsend deprivation scores, degree yes vs. no, 
self-report diabetes, hypertension and CHD. Each three-way interaction includes the two-way interactions plus main effects in the 
model(s).  Each dependent variable (cognitive score) is underlined in the left-hand column.
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Supplementary Table e-4 – lifestyle and APOE e4 intercorrelations.  
Odds ratios reflect logistic regressions of a 1-unit change in the independent variable (y-
axis) vs. dependent variable (x-axis). *P<0.05; **P<0.001.  
 
  
Odds ratio (CI’s) Smoking Alcohol Obesity Physical 
activity  
Degree  APOE 
e4 
Smoking status 
(never/previous 
vs. never)  
-      
Alcohol (heavy vs. 
not) 
1.88 
(1.81-
1.94) ** 
-     
Obesity (obese vs. 
not) 
1.00 
(0.92-
1.09) 
0.22 
(0.21-
0.25) ** 
-    
Physical activity 
quintile (1-5; 
ordinal).  
0.96 
(0.88-
1.06) 
0.97 
(0.89-
1.05) 
1.09 
(0.09-
1.33) 
-  
 
 
Degree (college 
and above vs. not) 
0.51 
(0.49-
0.52) ** 
2.19 
(2.14-
2.24) ** 
0.58 
(0.55-
0.62) ** 
0.89 
(0.84=0.93) 
** 
-  
APOE e4 allele 
presence (vs. 
absence)  
0.95 
(0.93 to 
0.98) ** 
1.01 
(0.98-
1.03) 
0.98 
(0.93-
1.04) 
0.98 (0.93-
1.04) 
1.02 
(1.00-
1.03)* 
- 
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Supplementary Table e-5 – alcohol intake by APOE e4 status.  
SD = standard deviation. Scores are medians for reaction time and trail making test 
scores because they were not normally distributed. Reasoning and Digit symbol scores 
are means.  
 
  
 APOE e4 absent  APOE e4 present  
 Light 
drinker 
Heavy 
drinker 
Light 
drinker 
Heavy 
drinker 
Reasoning scores (mean; 
SD) 
5.89 (2.07) 6.54 (2.09) 5.85 (2.07) 6.56 (2.08) 
N 18,773 16,708 6,608 6,145 
     
Reaction time (msecs; 
median and interquartile 
range) 
543 (485-
617) 
531 (470-
601) 
543 (484-
614) 
531 (477-
598) 
N 56,389 50,038 20,652 18,424 
     
Trail making test A (secs; 
median and interquartile 
range) 
35.88 
(29.20 – 
45.18) 
35.41 
(29.33-
43.97) 
36.28 
(29.54-
46.18) 
35.26 
(29.31-
43.54) 
N 10,656 12,483 3,859 4,465 
     
Trail making test B (secs 
median and interquartile 
range) 
61.11 
(49.40 – 
76.80) 
61.05 
(49.78-
76.03) 
62.00 
(50.06 – 
78.88) 
60.96 
(49.77 – 
75.11) 
N 10,659 12,504 3,859 4,469 
     
Digit symbol substitution 
score (mean; SD) 
19.62 (5.26) 19.66 
(4.96) 
19.50 (5.39) 19.51 (5.12) 
N 12,434 14,297 4,476 5,152 
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Supplementary Figure e-1: three-way APOE e4, alcohol intake and sex plot for 
reasoning scores (estimated marginal means based on fully-adjusted model; see 
‘analysis’). 
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